Antisense approaches for the treatment of cancer

Cancer Investigation

Volumn 18, Issue 7, 2000, Pages 635-650

  Monia, B P ^a   Holmlund, J ^a   Dorr, F A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CGP 69846A; DNA METHYLTRANSFERASE; GENE EXPRESSION MODULATOR 231; ISIS 2503; ISIS 3521; LR 3001; MESSENGER RNA; MG 98; OBLIMERSEN; PROTEIN BCL 2; PROTEIN KINASE C; RAF PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLEEDING; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; DNA TRANSCRIPTION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LYMPHOMA; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RNA HYBRIDIZATION; RNA TRANSLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0033814862     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009032830     Document Type: Review

References (93)

1. Role of chromosome translocations in human neoplasia
2. Oncogene amplification in tumor cells
3. Ras oncogenes in human cancer: A review
4. Molecular themes in oncogenesis
5. Chromosomal translocations in human cancer
6. Oncogenes and tumor suppressor genes
7. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
8. Therapeutic applications of oligonucleotides
9. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression
10. Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides
11. Progress in antisense oligonucleotide therapeutics
12. 2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
13. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
14. Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicological properties of phosphorothioate oligodeoxynucleotides
15. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance
16. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
17. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
18. Results of a phase I clinical trial of Bcl-2 antisense molecule G3139 (GENTA) in patients with non-Hodgkin's lymphoma (NHL)
19. Bcl-2 antisense therapy chemosensitizes human melanoma SCID mice
20. Transmission of fowl leukosis through chick embryos and adult chicks
21. Isolation and characterization of a novel member of the gene family encoding the cAMP response element-binding protein CRE-BPI
22. Viral myb oncogene encodes a sequence-specific DNA-binding activity
23. Avian myeloblastosis virus and E26 virus oncogene products are nuclear proteins
24. Subcellular localization of proteins encoded by oncogenes of avian myeloblastosis virus and avian leukemia virus E26 and by chicken c-myb gene
25. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma
26. Cytogenetics of human malignant melanoma and premalignant lesions
27. Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas
28. Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia
29. Synergistic activation of the chicken mim-1 gene by v-myb and C/EBP transcription factors
30. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: An in vitro study relevant to bone marrow purging
31. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines
32. Nucleic acid therapeutics for human leukemia: Development and early clinical experience with oligodeoxynucleotides directed at c-myb
33. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides
34. Oligodeoxynucleotide therapeutics for human myelogenous leukemia: Interim results
35. Bone marrow purging with oligodeoxynucleotides
36. Antisense strategies in the treatment of leukemias
37. Nucleic acid therapeutics: State of the art and future prospects
38. Role of Raf-1 serine/threonine protein kinase in growth factor signal transduction
39. Activation of the MAP kinase pathway by the protein kinase raf
40. The ins and outs of Raf kinases
41. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase
42. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
43. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma
44. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation
45. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo
46. Disruption of the MAP kinase signaling pathway using antisense oligonucleotide inhibitors targeted to RAS and RAF kinase
47. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf- 1-MEK-mitogen-activated protein kinase signalling pathway
48. A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules
49. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo
50. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
51. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase
52. Phase I/pharmacokinetic/pharmacodynamic trials of Raf-1 antisense ODN (ISIS 5132, CGP 69846A)
53. Phase I trial of C-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer
54. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
55. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis - Thirty-third G. H. A. Clowes Memorial Award Lecture
56. Alterations in murine keratinocyte differentiation induced by activated rasHa genes are mediated by protein kinase C-alpha
57. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts
58. Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-I cDNA
59. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression
60. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype
61. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule I (ICAM-1) mRNA by phorbol esters
62. Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells
63. PKC-epsilon is required for mechano-sensitive activation of ERK1/2 in endothelial cells
64. Antisense oligonucleotides as inhibitors of signal transduction: Development from research tools to therapeutic agents
65. Identification and characterization of second-generation antisense oligonucleotides
66. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
67. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide
68. Phase I/pharmacokinetic (PK) trial of a Protein Kinase C-α antisense oligonucleotide, ISIS 3521 (CGP 64128A), administered thrice weekly
69. Phase I study of an antisense oligonucleotide to protein kinase C- (ISIS 3251/CGP 64128A) in patients with cancer
70. The ras oncogene
71. The molecular genetics of cancer
72. Genetic alterations during colorectal-tumor development
73. Pharmacology of antisense therapeutic agents: Cancer and inflammation
74. Nucleotide sequence analysis of the T24 human bladder carcinoma oncogene
75. A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene
76. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
77. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides
78. In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development
79. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts
80. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation
81. Phase I and pharmacokinetic trial of ISIS 2503, a 20-mer antisense oligonucleotide against H-ras, by 14-day continuous infusion (CIV) in patients with advanced cancer
82. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, administered by a 24-hour (hr) weekly infusion to patients (pts) with advanced cancer
83. Protein kinases
84. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignacy: New approaches to therapy
85. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells
86. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase
87. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth
88. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA
89. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype
90. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct
91. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice
92. Antisense oligonucleotides absorbed to polyalkyl-cyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice
93. Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense Ha-Ras DNA-in vitro and in vivo studies